Sugi Predict

Sugi Predict / Compounds / SCHEMBL20133673

SCHEMBL20133673

SCHEMBL20133673

Cc1nc(C)c(NC2CCN(c3ccccc3C#N)CC2)cc1C=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTOR P42345 6/20 0.45
▸ RPTOR Q8N122 6/20 0.45
▸ MLST8 Q9BVC4 6/20 0.45
▸ PHGDH O43175 1/20 0.41
▸ ACHE P22303 3/20 0.38
▸ DRD4 P21917 4/20 0.37
▸ DRD2 P14416 2/20 0.37
▸ DRD3 P35462 2/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ HTR2A P28223 1/20 0.37
▸ THPO P40225 1/20 0.37
▸ HIF1A Q16665 1/20 0.37
▸ GRM5 P41594 1/20 0.36
▸ AR P10275 1/20 0.36
▸ EHMT2 Q96KQ7 1/20 0.36
▸ GMNN O75496 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20133677 0.89 MTOR (0.44) MTORRPTORMLST8PHGDHACHE
SCHEMBL20140843 0.85 MTOR (0.44) MTORRPTORMLST8PHGDHACHE
SCHEMBL20133665 0.83 MTOR (0.53) MTORRPTORMLST8PHGDHDRD4
SCHEMBL20133699 0.82 MTOR (0.61) MTORRPTORMLST8PHGDHDRD4
SCHEMBL20140652 0.81 PHGDH (0.45) PHGDHDRD4DRD2DRD3KDM4E
SCHEMBL20133678 0.79 MTOR (0.59) MTORRPTORMLST8PHGDHKDM4E
SCHEMBL20133773 0.78 MTOR (0.55) MTORRPTORMLST8PHGDHACHE
SCHEMBL20149869 0.76 MTOR (0.56) MTORRPTORMLST8PHGDHACHE
SCHEMBL20149885 0.75 MTOR (0.54) MTORRPTORMLST8KDM4EALDH1A1
SCHEMBL20150229 0.75 MTOR (0.51) MTORRPTORMLST8PHGDHDRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10844013-B2 Phenyl amino piperidine mTORC inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2020-11-24 — — US disclosed
US-20200207716-A1 PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2020-07-02 — — US disclosed
EP-3538091-A1 PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF Navitor Pharmaceuticals, Inc. (US) 2019-09-18 — — EP disclosed
US-10414727-B2 Phenyl amino piperidine mTORC inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2019-09-17 — — US disclosed
WO-2018089499-A1 PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. (US) 2018-05-17 — — WO disclosed
WO-2018089499-A1 PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. (US) 2018-05-17 — — WO disclosed
US-20180127370-A1 PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2018-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10844013-B2 Phenyl amino piperidine mTORC inhibitors and uses thereof MTOR, RICTOR, RPTOR MTOR 1/4885RPTOR 3/4885MLST8 7/4885
US-10414727-B2 Phenyl amino piperidine mTORC inhibitors and uses thereof MTOR, RICTOR, RPTOR MTOR 1/4885RPTOR 3/4885MLST8 7/4885
US-20180127370-A1 PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF MTOR, RICTOR, RPTOR MTOR 1/4885RPTOR 3/4885MLST8 7/4885
US-20200207716-A1 PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF MTOR, RICTOR, RPTOR MTOR 1/4885RPTOR 3/4885MLST8 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.